Sort by

Send to

Choose Destination

Links from PubMed

Items: 18


Synthesis of aza and carbocyclic β-carbolines for the treatment of alcohol abuse. Regiospecific solution to the problem of 3,6-disubstituted β- and aza-β-carboline specificity.

Phani Babu Tiruveedhula VV, Methuku KR, Deschamps JR, Cook JM.

Org Biomol Chem. 2015 Nov 21;13(43):10705-15. doi: 10.1039/c5ob01572c.


A single dose of kudzu extract reduces alcohol consumption in a binge drinking paradigm.

Penetar DM, Toto LH, Lee DY, Lukas SE.

Drug Alcohol Depend. 2015 Aug 1;153:194-200. doi: 10.1016/j.drugalcdep.2015.05.025. Epub 2015 May 27.


Randomized controlled trial of a mobile phone intervention for improving adherence to naltrexone for alcohol use disorders.

Stoner SA, Arenella PB, Hendershot CS.

PLoS One. 2015 Apr 24;10(4):e0124613. doi: 10.1371/journal.pone.0124613. eCollection 2015.


Effects of naltrexone on neural and subjective response to alcohol in treatment-seeking alcohol-dependent patients.

Spagnolo PA, Ramchandani VA, Schwandt ML, Zhang L, Blaine SK, Usala JM, Diamond KA, Phillips MJ, George DT, Momenan R, Heilig M.

Alcohol Clin Exp Res. 2014 Dec;38(12):3024-32. doi: 10.1111/acer.12581.


Use of novel technology-based techniques to improve alcohol-related outcomes in clinical trials.

Gurvich EM, Kenna GA, Leggio L.

Alcohol Alcohol. 2013 Nov-Dec;48(6):712-9. doi: 10.1093/alcalc/agt134. Epub 2013 Aug 17. Review.


A literature review of cost-benefit analyses for the treatment of alcohol dependence.

Popova S, Mohapatra S, Patra J, Duhig A, Rehm J.

Int J Environ Res Public Health. 2011 Aug;8(8):3351-64. doi: 10.3390/ijerph8083351. Epub 2011 Aug 16. Review.


Development of a two-step route to 3-PBC and βCCt, two agents active against alcohol self-administration in rodent and primate models.

Namjoshi OA, Gryboski A, Fonseca GO, Van Linn ML, Wang ZJ, Deschamps JR, Cook JM.

J Org Chem. 2011 Jun 3;76(11):4721-7. doi: 10.1021/jo200425m. Epub 2011 May 4.


The pharmacotherapy of alcohol dependence: a state of the art review.

De Sousa A.

Mens Sana Monogr. 2010 Jan;8(1):69-82. doi: 10.4103/0973-1229.58820.


A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype.

Kranzler HR, Armeli S, Tennen H, Covault J, Feinn R, Arias AJ, Pettinati H, Oncken C.

J Clin Psychopharmacol. 2011 Feb;31(1):22-30. doi: 10.1097/JCP.0b013e31820465fa. Erratum in: J Clin Psychopharmacol. 2011 Oct;31(5):576.


Design, synthesis, and subtype selectivity of 3,6-disubstituted β-carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents for treatment of alcohol abuse.

Yin W, Majumder S, Clayton T, Petrou S, VanLinn ML, Namjoshi OA, Ma C, Cromer BA, Roth BL, Platt DM, Cook JM.

Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. doi: 10.1016/j.bmc.2010.08.049. Epub 2010 Sep 29.


Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations.

Knudsen HK, Roman PM, Oser CB.

J Addict Med. 2010 Jun;4(2):99-107. doi: 10.1097/ADM.0b013e3181b41a32.


Persistence with oral naltrexone for alcohol treatment: implications for health-care utilization.

Kranzler HR, Stephenson JJ, Montejano L, Wang S, Gastfriend DR.

Addiction. 2008 Nov;103(11):1801-8. doi: 10.1111/j.1360-0443.2008.02345.x.


Acute interaction of baclofen in combination with alcohol in heavy social drinkers.

Evans SM, Bisaga A.

Alcohol Clin Exp Res. 2009 Jan;33(1):19-30. doi: 10.1111/j.1530-0277.2008.00805.x. Epub 2008 Oct 6.


Relationship between medication adherence and treatment outcomes: the COMBINE study.

Zweben A, Pettinati HM, Weiss RD, Youngblood M, Cox CE, Mattson ME, Gorroochurn P, Ciraulo D.

Alcohol Clin Exp Res. 2008 Sep;32(9):1661-9. doi: 10.1111/j.1530-0277.2008.00743.x. Epub 2008 Jul 9.


The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters.

Knudsen HK, Ducharme LJ, Roman PM.

Drug Alcohol Depend. 2007 Mar 16;87(2-3):164-74. Epub 2006 Sep 12.


Design of naltrexone-loaded hydrolyzable crosslinked nanoparticles.

Yin W, Akala EO, Taylor RE.

Int J Pharm. 2002 Sep 5;244(1-2):9-19.

Items per page

Supplemental Content

Write to the Help Desk